This is a regulatory disclosure submitted to BSE Limited and National Stock Exchange of India Ltd. pursuant to Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
The Board of Directors of Nath Bio-Genes (India) Limited will hold a meeting on Wednesday, 29th July 2026 to:
- Consider, approve and take on record the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June 2026
- Transact any other business with the permission of the Chair
The Company has implemented a "Trading Window" closure under the Code of Conduct for Prevention of Insider Trading, effective from 30th June 2026. The Trading Window will remain closed until 48 hours after the declaration of the financial results and is scheduled to reopen on 1st August 2026.
Financial Impact
Financial results for the quarter are pending board approval and have not been disclosed in this filing.